Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
G Masi, F Loupakis, L Salvatore, L Fornaro… - The lancet …, 2010 - thelancet.com
Background The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has
been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 …
been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 …
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and …
C Cremolini, F Loupakis, C Antoniotti, C Lupi… - The Lancet …, 2015 - thelancet.com
Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and
irinotecan) plus bevacizumab significantly improved progression-free survival of patients …
irinotecan) plus bevacizumab significantly improved progression-free survival of patients …
[HTML][HTML] Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer
F Loupakis, C Cremolini, G Masi… - … England Journal of …, 2014 - Mass Medical Soc
Background A fluoropyrimidine plus irinotecan or oxaliplatin, combined with bevacizumab (a
monoclonal antibody against vascular endothelial growth factor), is standard first-line …
monoclonal antibody against vascular endothelial growth factor), is standard first-line …
[HTML][HTML] Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
E Van Cutsem, F Rivera, S Berry, A Kretzschmar… - Annals of …, 2009 - Elsevier
Background Bevacizumab significantly improves survival when added to chemotherapy for
metastatic colorectal cancer (mCRC). The Bevacizumab Expanded Access Trial (BEAT) …
metastatic colorectal cancer (mCRC). The Bevacizumab Expanded Access Trial (BEAT) …
Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II …
C Emmanouilides, G Sfakiotaki, N Androulakis… - BMC cancer, 2007 - Springer
Purpose To evaluate the efficacy and the toxicity of front line FOLFOX4 combined with
bevacizumab in patients with metastatsic CRC (mCRC). Patients and Methods …
bevacizumab in patients with metastatsic CRC (mCRC). Patients and Methods …
[HTML][HTML] FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized …
C Cremolini, F Loupakis, G Masi, S Lonardi… - Annals of …, 2016 - Elsevier
Background FOLFOXIRI plus bevacizumab is a valid option as upfront treatment for
metastatic colorectal cancer (mCRC) patients. While several trials investigated the effect of …
metastatic colorectal cancer (mCRC) patients. While several trials investigated the effect of …
Phase II randomized trial of sequential or concurrent FOLFOXIRI‐bevacizumab versus FOLFOX‐bevacizumab for metastatic colorectal cancer (STEAM)
HI Hurwitz, BR Tan, JA Reeves, H Xiong… - The …, 2019 - academic.oup.com
Background First‐line treatment for metastatic colorectal cancer (mCRC) typically entails a
biologic such as bevacizumab (BEV) with 5‐fluorouracil/leucovorin/oxaliplatin (FOLFOX) or …
biologic such as bevacizumab (BEV) with 5‐fluorouracil/leucovorin/oxaliplatin (FOLFOX) or …
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer
Background: Bevacizumab (Avastin®) significantly improves overall survival (OS) and
progression-free survival (PFS) when combined with first-line irinotecan (IFL) plus bolus 5 …
progression-free survival (PFS) when combined with first-line irinotecan (IFL) plus bolus 5 …
[HTML][HTML] Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a …
BACKGROUND: The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and
irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC). This …
irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC). This …
[HTML][HTML] Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized …
A Passardi, O Nanni, D Tassinari, D Turci, L Cavanna… - Annals of …, 2015 - Elsevier
Background We report the results from a first-line phase III randomized clinical trial on
metastatic colorectal cancer (mCRC) aimed at evaluating the effectiveness of adding …
metastatic colorectal cancer (mCRC) aimed at evaluating the effectiveness of adding …